Примери за използване на Technology developer на Английски и техните преводи на Български
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
(f) information on studies andstudy registries available to the health technology developer.
The information to be provided by the health technology developer relates to the most up-to-date and public data.
The designated sub-group shall review the joint clinical assessment report andsummary report taking into account the comments provided by the health technology developer.
In the cases referred to under points(a),(b),(ba) and(bb)of the first subparagraph, the technology developer shall submit the additional information.
The designated sub-group and the health technology developer concerned shall hold a joint meeting based on the documentation described in first subparagraph.
The designated sub-group shall consider the conclusions referred to in paragraph 2 andinvite the health technology developer to submit comments by a specified deadline.
The health technology developer, patients, health professionals and clinical experts may submit comments during the joint scientific consultation.
Where the Coordination Group refuses the request, it shall inform the health technology developer thereof and explain the reasons having regard to the criteria laid down in paragraph 2.
When preparing the study, the Coordination Group shall ensure that commercially confidential information provided by the health technology developer is adequately protected.
The Coordination Group shall inform the submitting health technology developer accordingly and include summary information on those reports in its annual report.
The Coordination Group shall provide the approved joint clinical assessment report andthe summary report to the submitting health technology developer and the Commission.
Where new clinical data become available during the process,the health technology developer concerned shall also proactively communicate this new information to the assessor.
(ba) the health technology developer requests an update on the grounds that additional evidence is made available for which the Coordination Group would need to reconsider the conclusions of the initial assessment.
The assessor shall provide the draft joint scientific consultation report to the submitting health technology developer and set a time-frame in which the developer may submit comments.
Where the submitting health technology developer withdraws the application for a marketing authorisation, giving reasons, or where the European Medicines Agency terminates an assessment, the Coordination Group shall be informed so that it terminates the joint clinical assessment procedure.
Within 15 working days after receipt of the request, the Coordination Group shall inform the requesting health technology developer whether or not it will engage in the joint scientific consultation.
The designated sub-group shall request the health technology developer to submit the available and up-to-date documentation containing all stages of information processing, data and studies necessary for the joint scientific consultation, such as available data from all tests performed and from all the studies in which the technology was used.
The assessor shall provide the draft joint clinical assessment report andthe summary report to the submitting health technology developer and set a time-frame in which the developer may submit comments.
The designated sub-group shall request the health technology developer to submit the documentation containing the information, data and evidence necessary for the joint scientific consultation.
The Coordination Group shall provide the approved joint clinical assessment report andthe summary report to the submitting health technology developer and the Commission, which shall include both reports on the IT platform.
The designated sub-groupshall ensure that stakeholders, including patientthe health technology developer concerned and patients, consumers and clinical experts are given an opportunity to provide comments during the preparation of the draft joint scientific consultation report and set a time-frame in which they may submit comments.
It shall approve and submit the final joint clinical assessment report, the summary report andan explanatory document detailing how the objections were addressed to the submitting health technology developer and the Commission.
When receiving the joint clinical assessment report and the summary report,the health technology developer may hand in a detailed objection in writing to the Coordination Group within seven working days.
The Coordination Group shall approve and submit the final joint clinical assessment report,the summary report and an explanatory document setting out how the objections of the submitting health technology developer and the Commission were addressed.
Upon receipt of the approved joint clinical assessment report and summary report,the submitting health technology developer may notify its objections in writing to the Coordination Group and the Commission within seven working days.
The health technology developer conducts at least one randomised controlled clinical trial, comparing its health technology in terms of clinically relevant outcomes with an active comparator considered among the best current proven intervention at the time the trial was designed(standard treatment), or the most common intervention when no standard treatment exists.
Upon receipt of the approved joint clinical assessment report and summary report,the submitting health technology developer may object in writing to the Coordination Group and the Commission within 7 working days.
(j) where practically feasible andethically justifiable, the health technology developer conducts at least one randomised controlled clinical trial, comparing its health technology in terms of clinically relevant outcomes with an active comparator considered among the best current proven intervention at the time the trial was designed(standard treatment), or the most common intervention when no standard treatment exists.
Where, at any stage in the preparation of the draft joint scientific consultation report,the assessor considers that additional evidence from a health technology developer is necessary in order to complete the report, it may request the designated sub-group to suspend the time period set for the preparation of the report and to request the additional evidence from the health technology developer.